 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C44H88NO8P |
| Molecular Weight | 790.15 |
| Exact Mass | 789.624 |
| Elemental Analysis | C, 66.88; H, 11.23; N, 1.77; O, 16.20; P, 3.92 |
| CAS # | 816-94-4 |
| Related CAS # | 1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d70;56952-01-3;1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d74;326495-38-9;1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d79;326495-39-0;1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d83;326495-40-3;1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d4;326495-35-6;1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d9;326495-36-7;1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d13;326495-37-8 |
| PubChem CID | 94190 |
| Appearance | Typically exists as white to off-white solids at room temperature |
| Melting Point | 236 °C |
| LogP | 13 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 44 |
| Heavy Atom Count | 54 |
| Complexity | 888 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | [C@@H](COC(=O)CCCCCCCCCCCCCCCCC)(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC |
| InChi Key | NRJAVPSFFCBXDT-HUESYALOSA-N |
| InChi Code | InChI=1S/C44H88NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h42H,6-41H2,1-5H3/t42-/m1/s1 |
| Chemical Name | 1,2-Distearoyl-sn-glycero-3-phosphocholine |
| Synonyms | 1,2-Distearoyl-sn-glycero-3-PC; 1,2-Distearoyl-sn-glycero-3-phosphocholine; DSPC; Distearoyl phosphatidylcholine; (R)-2,3-Bis(stearoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate; 1,2-dioctadecanoyl-sn-glycero-3-phosphocholine; PC(18:0/18:0); 1,2-Distearoyl-sn-3-phosphacholine;Coatsome MC 8080; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | DSPC-cholesterol is found in the outer layer of empty lipid nanoparticle (LNP) systems without siRNA, but some of it is internalized with siRNA in loaded systems [2]. |
| ln Vivo | RNA interference (RNAi) therapeutics appear to offer substantial opportunities for future therapy. However, post-administration RNAi effectors are typically unable to reach disease target cells in vivo without the assistance of a delivery system or vector. The main focus of this review is on lipid-based nanoparticle (LNP) delivery systems in current research and development that have at least been shown to act as effective delivery systems for functional delivery of RNAi effectors to disease target cells in vivo. The potential utility of these LNP delivery systems is growing rapidly, and LNPs are emerging as the preferred synthetic delivery systems in preclinical studies and current nonviral RNAi effector clinical trials. Moreover, studies on LNP-mediated delivery in vivo are leading to the emergence of useful biophysical parameters and physical organic chemistry rules that provide a framework for understanding in vivo delivery behaviors and outcomes. These same parameters and rules should also suggest ways and means to develop next generations of LNPs with genuine utility and long-term clinical viability[1]. |
| References |
[1]. Andrew D Miller. Delivery of RNAi therapeutics: work in progress. Expert Rev Med Devices. 2013 Nov;10(6):781-811. [2]. On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale. 2019 Nov 21;11(45):21733-21739. |
| Additional Infomation |
1,2-distearoyl-sn-glycero-3-phosphocholine is a phosphatidylcholine 36:0 in which both phosphatidyl acyl groups are specified as stearoyl (octadecanoyl). It is functionally related to an octadecanoic acid. PC(18:0/18:0) is a metabolite found in or produced by Saccharomyces cerevisiae. See also: 1,2-Distearoyllecithin (annotation moved to). |
Solubility Data
| Solubility (In Vitro) | Ethanol: 12.5 mg/mL (15.82 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.25 mg/mL (1.58 mM) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (1.58 mM) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (1.58 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2656 mL | 6.3279 mL | 12.6558 mL | |
| 5 mM | 0.2531 mL | 1.2656 mL | 2.5312 mL | |
| 10 mM | 0.1266 mL | 0.6328 mL | 1.2656 mL |